Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Retained Earnings (2018 - 2026)

10x Genomics' Retained Earnings history spans 8 years, with the latest figure at $225000.0 for Q4 2025.

  • On a quarterly basis, Retained Earnings rose 100.02% to $225000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $225000.0, a 100.02% increase, with the full-year FY2025 number at $225000.0, up 100.02% from a year prior.
  • Retained Earnings hit $225000.0 in Q4 2025 for 10x Genomics, up from -$1.5 billion in the prior quarter.
  • Over the last five years, Retained Earnings for TXG hit a ceiling of $225000.0 in Q4 2025 and a floor of -$1.5 billion in Q1 2025.
  • Historically, Retained Earnings has averaged -$506.3 million across 5 years, with a median of -$4.1 million in 2022.
  • The widest YoY moves for Retained Earnings: up 100.05% in 2021, down 1991726.83% in 2021.
  • Tracing TXG's Retained Earnings over 5 years: stood at -$863.3 million in 2021, then soared by 99.5% to -$4.3 million in 2022, then surged by 90.1% to -$429000.0 in 2023, then crashed by 341869.0% to -$1.5 billion in 2024, then soared by 100.02% to $225000.0 in 2025.
  • Business Quant data shows Retained Earnings for TXG at $225000.0 in Q4 2025, -$1.5 billion in Q3 2025, and -$1.5 billion in Q2 2025.